2 million Ellume COVID-19 home tests recalled in the US

2 million Ellume COVID-19 home tests recalled in the US

The United States Food and Drug Administration (FDA) has classified a voluntary recall of 2 million COVID-19 home tests manufactured by Brisbane-based Ellume that were delivering ‘false positive’ results as a ‘Class 1 recall’ - the most serious type of recall it can issue.

“The FDA is continuing to work with Ellume to assess the company’s corrective actions, such as additional manufacturing checks and other corrective steps, to address the reason for the manufacturing issue, and to help ensure that it is resolved and will not recur,” the FDA said.

The recall comes after the FDA issued an alert earlier this week, notifying test users, caregivers and health care personnel about the potential for false positive results with certain lots of the Ellume-manufactured test, resulting from a manufacturing issue.

The manufacturing problem meant some people were receiving false positive results - indicating that a person has COVID-19 when they do not actually have it. Negative results were not affected by the manufacturing issue.

In a statement on the Ellume website, the company says it has isolated the cause and confirmed this incidence of false positives is limited to specific lots.

“We worked with the Food and Drug Administration (FDA) to voluntarily remove affected Ellume tests from the market. Importantly, the reliability of negative results is unaffected by this issue and are not included within this recall,” Ellume said.

“At Ellume, we remain committed to developing high-quality digital diagnostics that empower our users to manage their health. Patient well-being and product quality are our first priorities throughout every step of the manufacturing and supply chain process. We understand you are counting on us to do nothing less.

“We offer our sincere apologies for the stress or difficulties people may have experienced due to a false positive result. We have and will continue to work diligently to ensure test accuracy, in all cases.”

The news comes 11 months after the FDA issued an Emergency Use Authorisation to permit the use of the Ellume COVID-19 test in the US.

Test users have been told to compare the lot number on the test carton to the lot numbers on Ellume’s website.

Ellume CEO Dr Sean Parsons has also issued a statement and an apology, noting that the recall may have “shaken the confidence of some of those who trusted Ellume to help them manage their health and to take back a bit of control of their lives during this pandemic”.

“To those individuals, I offer my sincere apologies – and the apologies of our entire company – for any stress or difficulties they may have experienced because of a false positive result,” Dr Parsons said.

“You have my personal commitment that we have learned from this experience, we have implemented additional controls to ensure our product meets our high quality standards and we are going to do everything in our power to regain your trust.”

Updated at 9.20am AEDT on 11 November 2021.

Enjoyed this article?

Don't miss out on the knowledge and insights to be gained from our daily news and features.

Subscribe today to unlock unlimited access to in-depth business coverage, expert analysis, and exclusive content across all devices.

Support independent journalism and stay informed with stories that matter to you.

Subscribe now and get 50% off your first year!

Four time-saving tips for automating your investment portfolio
Partner Content
In today's fast-paced investment landscape, time is a valuable commodity. Fortunately, w...
Etoro
Advertisement

Related Stories

“Not our desired outcome”: Telix withdraws from $300m Nasdaq IPO

“Not our desired outcome”: Telix withdraws from $300m Nasdaq IPO

Telix Pharmaceuticals (ASX: TLX), one of the nation’s largest...

CommBank joins new ‘intelligence loop’ to combat SMS phishing scams

CommBank joins new ‘intelligence loop’ to combat SMS phishing scams

In an effort to reduce the number of SMS phishing scam victims...

Stralis Aircraft secures funding to make commercial hydrogen planes a reality

Stralis Aircraft secures funding to make commercial hydrogen planes a reality

Brisbane-based Stralis Aircraft has become one step closer to its a...

A year after the PwC scandal, the furore is gone – as well as the appetite for structural change

A year after the PwC scandal, the furore is gone – as well as the appetite for structural change

It was a scandal that rocked the shaky foundations of Australia&rsq...